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Abstract

Background
HIV infection and substance use synergistically impact health outcomes of people with HIV. In this study, we assessed the prevalence of substance use among women living with HIV (WLWH) and compared them with
expected values from general data.

Methods
Cigarette smoking, frequency of alcohol consumption, last-month non-prescribed cannabis use (vs. last-year use), and last 3 months regular (≥once/week) and occasional (-–

2015 Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS; N = 1422) and compared with general population women from the 2013-–2014 Canadian Community Health Survey
(CCHS; N = 46,831). Age/ethnoracial-standardized prevalence differences (SPD) and 95% confidence intervals (CI) were reported.

Results
Compared to expected estimates from general population women, a higher proportion of WLWH reported daily cigarette smoking (SPD: 26.8% [95% CI: 23.9, 29.7]), smoking ≥20 cigarettes/day (SPD: 11.6% [9.8, 13.6]),
regular non-prescribed cannabis use (SPD: 8.0% [4.1, 8.6]), regular crack/cocaine use (SPD: 16.7% [13.1, 20.9]), regular/occasional speed use (SPD: 2.4% [1.2, 4.7]), and heroin use (SPD: 11.2% [8.3, 15.0]). However, WLWH
reported lower frequencies of alcohol consumption and binge drinking than their counterparts in the general population.

Conclusions
Cigarette smoking and illicit drug use, but not alcohol use or binge drinking, were more prevalent in WLWH than would be expected for Canadian women with a similar age and ethnoracial group profile. These findings
may indicate the need for women-centered harm reduction programs to improve health outcomes of WLWH in Canada.
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1 Introduction
Substance use is a common health risk behavior among people living with HIV (PLWH), who have a demonstrated greater prevalence than their general population counterparts (Ikeda et al., 2016; Mdodo et al., 2015; Tron et
al., 2014). Substance use is considered a major barrier to successful HIV care and treatment (Cofrancesco et al., 2008; Cook et al., 2009; Durvasula and Miller, 2014; Gonzalez et al., 2011; Hicks et al., 2007; Malta et al., 2008) despite
the substantial advances obtained from combination antiretroviral therapy (cART), e.g., improved life expectancy in PLWH (Antiretroviral Therapy Cohort Collaboration, 200 (Here is the reference that looked like being missed but it should
be actually cited here as: (Antiretroviral Therapy Cohort Collaboration, 2008))8). Substance use independently or by interaction with other factors such as psychiatric disorders and socioeconomic marginalization has the potential to limit the

remarkable benefits of cART and pose additional barriers to HIV prevention efforts and medical care (Durvasula and Miller, 2014; Feldman et al., 2006; Gonzalez-Serna et al., 2014; Gonzalez et al., 2011; Hicks et al., 2007; Malta et al.,
2008; Petoumenos and Law, 2016; Vagenas et al., 2015).
Previous studies have reported the negative impacts of tobacco smoking (Feldman et al., 2006), problematic alcohol consumption (Vagenas et al., 2015), and illicit drug use (e.g., heroin) (Cofrancesco et al., 2008; Hicks et al.,
2007) on HIV care cascade outcomes such as cART non-adherence. The optimal levels of these outcomes are critical in promoting the health of PLWH and maintaining treatment as prevention (TasP) targets (Cohen et al., 2016). Beyond
its interruption of care and treatment, substance use can also interfere with cART metabolism and virological response (Barve et al., 2010; Kumar et al., 2015), and contribute to excess mortality (Feldman et al., 2006; Helleberg et al.,
2015). For example, in a study of 17,995 PLWH on treatment, smoking increased the rate of death by 1.94 times, with 1.84 and 2.41 times in men and women with HIV, respectively (Helleberg et al., 2015).
Substance use vulnerability appears to have greater impacts on HIV and clinical outcomes among women than men with HIV. For example, women with injection drug use (IDU) history and Indigenous ancestry had lower
optimal adherence to treatment (47.8%) relative to their male HIV-positive counterparts with (57.7%) and without (83.8%) such vulnerabilities (Puskas et al., 2017). Women with IDU history were also found to be 18% less likely to
achieve HIV RNA viral suppression than their male counterparts (Cescon et al., 2013). Other than the unique experiences of HIV infection among women (e.g., pregnancy), drug use along with greater experiences of other psychosocial,
economic and structural challenges may account for gender-related differences in HIV outcomes (Cescon et al., 2013; Kuyper et al., 2004; Wood et al., 2008).
However, substance use prevalence among women living with HIV (WLWH) has not been well-characterized, particularly in Canada. Population-based research has either overlooked collecting data on WLWH or has not had the
adequate sample size to provide estimates for WLWH and comparisons to the broader population (Loutfy et al., 2013; Webster et al., 2018). Women now constitute more than half of all individuals living with HIV worldwide (UNAIDS,
2014) and represent nearly one-fourth of the estimated 75,500 PLWH in Canada; almost doubled from the 1990s (Public Health Agency of Canada, 2015). Understanding the prevalence of substance use in a geographically diverse
sample of WLWH relative to general population women is important because of the profound implications for HIV management and to assess the need for harm reduction and socio-structural supports for women who use substances.
Therefore, the objective of this research was to characterize the prevalence of cigarette smoking, alcohol consumption, non-prescribed cannabis use, and illicit drug use from the Canadian HIV Women’s Sexual and
Reproductive Cohort Study (CHIWOS), a large community-based research of WLWH in Canada. We estimated the prevalence for substance use in CHIWOS and compared them with data from HIV-negative women of the general
population, standardized to the age/ethnoracial distribution of WLWH. Our aim was to document substance use disparities between WLWH, to explore differences based on HIV status and to identify needs with regard to resource
allocation, particularly given the implications of substance use in the context of HIV-related medical care.

2 Methods
2.1 Participants

2.1.1 CHIWOS Ssample
We used data from the baseline survey of the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) conducted between 2013 and 2015. CHIWOS is a large community-based research of WLWH (≥16 years; transinclusive: 3.8%), residing in British Columbia (BC), Ontario, and Quebec. Study design and sampling procedure were published elsewhere (Loutfy et al., 2017). Briefly, applying the Meaningful Involvement of Women Living with HIV/AIDS (MIWA) principle,
reflecting the recognition of the rights and responsibilities of individuals living with HIV as equal partners to actively engage throughout the design and delivery of HIV/AIDS services to strengthen the responses to HIV/AIDS epidemics (UNAIDS, 2007). A
sample of 1422 WLWH was recruited from HIV clinics, AIDS Service Organizations, peers, and online networks (Webster et al., 2018). The survey was administered by Peer Research Associates (PRAs), many of whom also shared the experience of living
with HIV were hired and trained in community-based research conduction (Loutfy et al., 2017). The averaged 120-minute-long surveys were administered either through in-person interviews at the clinic, community sites, at the participants’ homes or via
phone/Skype. CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University of British Columbia/Providence Health, Women’s College Hospital and McGill University Health Centre.

2.1.2 CCHS Ssample
We used data from the 2013-–2014 cycle of the Canadian Community Health Survey (CCHS), a nation-wide cross-sectional survey administered by Statistics Canada. Detailed documentation is available elsewhere (Canadian Community Health
Survey, 2013). Briefly, CCHS is designed to provide nationally representative estimates on health status, health care utilization, and health determinants of Canadians aged 12 years or older residing in private dwellings of all provinces and territories
(~98% coverage), excluding populations living on reserves/Indigenous settlements, institutions, Canadian Force Bases, and some remote regions. Data are collected using computer-assisted personal and telephone interview software. Consistent with
CHIWOS, CCHS analyses were restricted to women aged ≥16 years old, residing in the three provinces (analytic sample = 46,851). Measures of cigarette smoking, alcohol consumption, non-prescribed cannabis use and illicit drug use with similar content
and wording were compared between the two surveys.

2.2 Measures
Although cigarette smoking and alcohol consumption were collected from all CCHS respondents, measures of drug use were not collected in Ontario and Quebec; for comparability, we provided estimates of drug use for only
BC in CHIWOS.

2.2.1 Cigarette Ssmoking
In CHIWOS, cigarette smoking history was measured as, “What is your cigarette (tobacco) smoking history?” with four response options (regular, occasional, former, and never). In CCHS, the same question was asked with three response options
(daily, occasionally, not at all). To be consistent with the CCHS definition, we categorized WLWH who reported at least one cigarette/day (equivalently, at least 30 cigarettes/month) as “daily” smokers irrespective of how they were self-identified. As such, 67
self-identified occasional smokers were re-coded as daily smokers, and two cases who reported cigarette smoking regularly were re-coded as occasional smokers. Two measures were created to compare the two surveys: a) nonsmokers at the time of
interview (i.e., former or none) versus current smokers (i.e., daily or occasional), and b) a three-category measure: nonsmokers, occasional smokers, and daily smokers. We also reported cigarette smoking intensity/quantity among current smokers. A fivecategory measure was created to compare the two surveys: nonsmokers (former or never), <1 cigarette/day or <30 cigarettes/month, 1-10 cigarettes/day, 11-–10 cigarettes/day, 11–19 cigarettes/day, and ≥20 cigarettes/day.

2.2.2 Alcohol Cconsumption
Last-year alcohol consumption pattern was examined in both CHIWOS and CCHS. A four-category comparable measure was created in each survey: none (did not drink in the past 12 months), ≤1 time/week, 2-–3 times/week, and ≥4 times/week.
CCHS measured the monthly pattern of binge drinking as, “How often in the past 12 months have you had 4 or more drinks on one occasion?” with six response categories: never, less than once a month, once a month, 2 to –3 times a month, once a
week, and more than once a week. The same question but in the last month was measured in CHIWOS, with an open-ended response option indicating the number of times. Binge drinking was compared between the two surveys under the assumption that
past-year binge drinking patterns were consistent with past month. We created a measure with similar response categories: no alcohol consumed, alcohol consumed but no binge drinking, binge drinking less than once a week (i.e., equivalently, less than 3
times a month), and binge drinking at least once a week (i.e., equivalently, four times or more a month). In CHIWOS, 33 women reported last-month binge drinking without specifying the number of times over the last month; therefore, instead of treating
them as missing values, we categorized them into “less than once a week.”

2.2.3 Drug Uuse
We compared the use of the following drugs available in the two surveys in BC: cannabis, cocaine or crack, speed (amphetamine), and heroin. CCHS asked respondents, “Have you used [any of these drugs] in the past 12 months?”, affirmative
responses were further followed, “How often [did you use any of these drugs in the past 12 months]?” with the following response options: less than once/ month, 1 to –3 times/month, once/week, more than once/week, and every day. CHIWOS measured
cannabis use as, “What is your cannabis use history?” with the following response categories: a) regularly in the last 30 days, b) occasionally in the last 30 days, c) used in the past year but not in the past 30 days, d) used in the past but not in the past year,

e) never used or only ever used it once or twice. To be consistent with CCHS, CHIWOS’s response options ‘b’ and ‘c’ were considered as occasional cannabis use. CHIWOS participants with a positive history of cannabis use were also followed, “Have you
used cannabis mainly for medicinal reasons or recreational reasons, or both?” We re-coded medicinal (prescribed) use of cannabis use as non-recreational use, while any other recreational reasons (alone or in combination with medicinal use) were
considered as non-prescribed cannabis use. This distinction was made as CCHS aimed to measure the use of illicit drugs, but not prescription drugs.
CHIWOS assessed the use of crack or cocaine, speed, and heroin over the last 3 months. Positive responses were additionally followed to measure the frequency of use as, daily, at least once/week, and less than once/week. The same information
was assessed in CCHS, but over the past year. Crack and cocaine use were measured in one single question in CCHS, while CHIWOS measured them separately. Therefore, daily use of any of these two drugs was considered as daily crack or cocaine use.
For comparison, we created a three-category measure for cannabis use and crack or cocaine use as: none (i.e., former or never), occasional (< once/week), and regular use (≥ once/week). As the absolute “n” for speed (amphetamine) and heroin
use did not meet the minimum CCHS vetting guideline, we combined regular and occasional use and then created a binary variable for each of these two drugs: none vs. occasional/regular use.

2.3 Data Aanalysis
We reported the prevalence and the 95% confidence intervals (CI) of each substance from the CHIWOS sample. We then obtained the prevalence of the same substances from the CCHS sample, using sampling weights that
Statistics Canada assigned each respondent to correspond to the number of Canadian residents they represent. The bootstrap variance estimation technique using a set of 500 replicates was used to obtain the 95% CI of the CCHS
estimates (Rust and Rao, 1996). To address the imbalanced distribution of age and ethnoracial groups, we used a standardization method which combines stratum-specific prevalence into a single summary estimate through taking a
weighted average (Rothman et al., 2008). Standardization obtains these weights in averaging from a standard population. In the present study, these weights were obtained from the CHIWOS dataset and applied to CCHS data. To do this,
we created a 16-category variable representing CHIWOS’s age and ethnoracial group distribution (i.e., four age categories: 16-35, 36-45, 46-–35, 36–45, 46–55, or >55; four ethnoracial categories: white, African, Caribbean, Black (ACB),
Indigenous, or other/multi-ethnicities). We then applied CHIWOS’s age and ethnoracial group distribution to CCHS in order to produce a second set of estimates in which CCHS and CHIWOS samples had a similar distribution with
respect to these two variables.
The standardized prevalence differences (SPD) were reported to quantify the differences between the two surveys for each substance use. The SPD is a commonly used measure for the purpose of population health assessment
and provides information on the public health impact. The SPD was computed by subtracting the CCHS expected estimates standardized to age and ethnoracial groups from the CHIWOS observed estimates; with an SPD greater than
zero (i.e., the null) denoting a greater prevalence of the given substance in WLWH. The SPD’s 95% CI was provided using the methods of variance estimates recovery (MOVER) (Zou and Donner, 2008 ), with 95% CI excluding 0
indicating statistical significance at p < 0.05. The analyses were performed using Stata version 15.

3 Results
3.1 Demographics
WLWH differed from the unstandardized general population data by age and ethnoracial groups as well as relationship status, education and yearly personal income levels (Table 1). Greater proportions of women in the
unstandardized general population were older and belonged to the white ethnoracial group than WLWH. Other characteristics of these two samples are presented in Table 1, along with the prevalence in the standardized CCHS data.
After standardization, the CCHS estimates had identical age and ethnoracial group structure. All subsequent comparisons of substance use were conducted using standardized data.

Table 1 The distribution of age, ethno-racial groups, relationship status, education status, and yearly personal income in the cohort of women with HIV compared with the assumed HIV-negative women of the general
population in Canada.
alt-text: Table 1
CHIWOS estimates (N = 1422)
N

CCHS estimates (N = 46,851)a

% (95% CI)

N

Unstandardized
% (95% CI)

Standardized
% (95% CI)d

Ethno-racial and age groups
White
16-–35 (years)

145

10.2 (8.7, 11.9)

8,749

21.1 (20.6, 21.7)

10.2e

36-–45

162

11.4 (9.8, 13.2)

4,582

11.2 (10.6, 11.5)

11.4

46-–55

178

12.5 (10.9, 14.3)

5,775

13.9 (13.4, 14.5)

12.5

> 55

99

7.0 (5.7, 8.4)

12,020

29.0 (28.5, 29.6)

7.0

16-351077.5 (6.3, 9.0)4571.1 (0.9, 1.3)7.5 36-–35

107

7.5 (6.3, 9.0)

457

1.1 (0.9, 1.3)

7.5

36–45

163

11.5 (9.9, 13.2)

280

0.7 (0.5, 0.9)

11.5

46-–55

111

7.8 (6.5, 9.3)

333

0.8 (0.6, 1.1)

7.8

> 55

37

2.6 (1.9, 3.6)

268

0.7 (0.5, 0.8)

2.6

16-–35

100

7.0 (5.8, 8.5)

424

1.0 (0.9, 1.2)

7.0

36-–55

120

8.4 (7.1, 10.0)

161

0.4 (0.3, 0.5)

8.4

36-–45

74

5.2 (4.2, 6.5)

176

0.4 (0.3, 0.5)

5.2

46-–55

24

1.7 (1.1, 2.5)

255

0.6 (0.5, 0.7)

1.7

20

1.4 (0.9, 2.2)

3,286

7.9 (7.4, 8.4)

1.4

36-–45

34

2.4 (1.7, 3.3)

1,837

4.4 (4.0, 4.9)

2.4

46-–55

37

2.6 (1.9, 3.6)

1,271

3.1 (2.7, 3.5)

2.6

> 55

11

0.8 (0.4, 1.4)

1,539

3.7 (3.4, 4.1)

0.8

Single

689

48.7 (46.1, 51.3)

10,438

24.3 (23.7, 24.8)

26.6 (24.6, 28.7)

Married, common-law

545

32.1 (29.7, 34.6)

24,971

58.0 (57.3, 58.7)

55.3 (52.7, 57.9)

Separated/divorced/widowed

271

19.2 (17.2, 21.3)

7,636

17.7 (17.2, 18.3)

18.1 (15.8, 20.4)

Less than high school

227

16.1 (14.2, 18.1)

6,568

15.4 (14.9, 16.0)

12.3 (11.0, 13.6)

High school completed

532

37.6 (35.1, 40.2)

10,514

24.7 (24.0, 25.4)

23.9 (21.9, 25.9)

Diploma/trade/college

456

32.2 (29.8, 34.7)

12,998

30.6 (29.8, 31.3)

35.9 (33.4, 38.4)

University degree (≥Bachelor’s degree)

200

14.1 (12.4, 16.1)

12,474

29.3 (28.6, 30.1)

27.9 (25.4, 30.4)

<20,000 CADc

997

70.3 (67.8, 72.6)

12,263

29.1 (28.4, 29.9)

28.1 (26.1, 30.0)

20,000 to <40,000 CAD

244

17.2 (15.3, 19.3)

10,425

24.8 (24.1, 25.5)

24.5 (22.4, 26.7)

≥ 40,000 CAD

144

10.1 (8.7, 11.8)

12,620

30.0 (29.2, 30.8)

33.1 (30.4, 35.8)

Not stated

34

2.4 (1.7, 3.3)

6,795

16.1 (15.5, 16.8)

14.3 (12.3, 16.3)

54

3.8 (2.9, 4.9)

---

---f

---f

Black

Indigenous

Others
16- 16–35

Relationship status

Education status

Yearly personal incomeb

Trans women

f

a

Out of 128,310 respondents, 46,851 (36.5%) were eligible for the current study: women aged 16+ residing in three provinces of BC, ON, QC.

b

Aged > 17 years old.

c

Canadian dollar (CAD).

d

95% CIs were not estimated for standardization variables.

e

Standardization made the two study populations identical with regard to age and ethno-racial group structure.

f

Not available as CCHS does not contain data identifying trans status.
Overall 83% and 87% of WLWH reported taking HIV medication and having a suppressed viral load (i.e., <50 c/mL), respectively. The median time living with HIV since diagnosis was 11 years (IQR: 7, 17) (data not shown).

3.2 Cigarette smoking (Table 2)
A higher prevalence of cigarette smoking frequency and intensity was reported among WLWH compared with estimates expected based on the age-/ethnoracial-standardized women of the general population. Current cigarette
smoking (i.e., daily/occasional) was reported by 43.7% of WLWH relative to 17.8% of the expected estimates of general population (SPD 25.9%), indicating that 25.9% (i.e., 259 per 1000) of WLWH reported current cigarette smoking,
in excess of what would be expected of Canadian women of similar ages/ethnoracial backgrounds. Daily cigarette smoking was reported by 40.7% of WLWH versus 13.9% of expected estimates from general population women (SPD
26.8%). WLWH tended to smoke a cigarette more intensely than the expected estimates of the general population.

Table 2 Comparison of cigarette smoking between women with HIV (N = 1422) and assumed HIV-negative women of the general population (N = 46,851).
alt-text: Table 2
Cigarette smoking measures

CHIWOS

CCHS estimates
CCHSb

SPDd
AER Std.c

Overall cigarette smoking
Non-smoker (i.e., former/never)

56.3
(53.7, 58.9)a

84.3
(83.7, 84.9)

82.2
(80.8, 83.7)

-25.9(-28.9, -−25.9
(−28.9, −22.9)

Current smokers (i.e., daily/occasional)

43.7
(41.1, 46.3)

15.7
(15.1, 16.3)

17.8
(16.3, 19.2)

25.9
(22.9, 28.9)

Non-smoker (i.e., former/never)

57.0
(54.4, 59.6)

84.3
(83.7, 84.9)

82.2
(80.8, 83.7)

-25.2(-28.2, -−25.2
(−28.2, −22.2)

Occasional smokerse

2.3
(1.6, 3.2)

3.8
(3.5, 4.2)

3.9
(3.2, 4.6)

-1.6 (-2.6, -−1.6
(−2.6, −0.5)

Daily smokersf

40.7
(38.1, 43.3)

11.9
(11.3, 12.4)

13.9
(12.5, 15.2)

26.8
(23.9, 29.7)

Non-smoker (i.e., former/never)g

57.0
(54.4, 59.6)

84.4
(83.8, 85.0)

82.4
(80.9, 83.9)

-25.4(-28.4, -−25.4
(−28.4, −22.4)

<1 cig/day or <30 cig/month

2.3
(1.6, 3.2)

2.5
(2.3, 2.8)

2.5
(2.1, 2.9)

-0.2 (-−0.2 (−1.0, 0.8)

1 to 10 cig/day

20.4
(18.3, 22.6)

6.6
(6.2, 7.0)

7.8
(6.7, 9.0)

12.6
(10.2, 15.1)

Current cigarette smoking status

Intensity of cigarette smoking

>10 to <20 cig/day

5.4
(4.4, 6.8)

3.2
(2.9, 3.4)

4.0
(3.2, 4.8)

1.4
(0.1, 3.0)

≥ 20 cig/day

14.9
(13.1, 16.9)

3.3
(3.0, 3.6)

3.3
(2.8, 3.8)

11.6
(9.8, 13.6)

a

Data are % (95% CI).

b

Unstandardized weighted estimates are reported and the 95% CI was constructed using bootstrap method.

c

Age- and ethno-racial-standardized expected estimates based on women of the general population from CCHS.

d

SPD: standardized prevalence difference (% (95% CI)); the 95% CI was constructed using MOVER algorithm.

e

Occasional smokers (<1 cigarette/day or <30 cigarettes/month).

f

Daily smokers (≥1 cigarettes/day or ≥30 cigarettes/month).

g

Because of missing values in variable intensity of cigarette smoking, the proportion of the first and second categories if different from the same categories in variable current cigarette smoking status, while the

absolute numbers is the same.

3.3 Alcohol Cconsumption (Table 3)
WLWH more frequently reported no alcohol consumption compared with the expected estimates (40.7% vs. 28.0%). The proportion of alcohol consumption categories among WLWH than expected estimates from standardized
general population data was: 46.8% vs. 52.2% consumed alcohol ≤1 time/week, 7.0% vs. 12.9% consumed alcohol 2-–3 times/week, and 5.5% vs. 6.9% consumed alcohol 4+ times/week. The monthly pattern of binge drinking in WLWH
was: 15.4% vs. 30.6% for less than once/week (SPD -−15.2%), and 4.6% vs. 3.9% for at least once/week (SPD 0.7%). The combination of these two categories showed that 20.0% of WLWH reported binge drinking at least once/month
compared with 34.5% in women of the general population.

Table 3 Comparison of alcohol consumption between women with HIV (N = 1422) and assumed HIV-negative women of the general population (N = 46,851).
alt-text: Table 3
CHIWOS

CCHS estimates
CCHSb

SPDd
AER Std.c

Alcohol consumption frequency
None (Never/none in specified time)

40.7
(38.2, 43.3)a

24.5
(23.7, 25.4)

28.0
(25.4, 30.5)

12.7
(9.1, 1.4)

≤1 time a week

46.8
(44.2, 49.4)

51.3
(50.4, 52.1)

52.2
(49.6, 54.8)

-5.4(-9.1, -1.7)2-−5.4
(−9.1, −1.7)

2–3 times a week

7.0
(5.7, 8.4)

15.1
(14.5, 15.7)

12.9
(11.5, 14.1)

-5.9(-7.7, -−5.9
(−7.7, −3.9)

4+ times a week

5.5
(4.4, 6.8)

9.1
(8.7, 9.5)

6.9
(5.8, 8.1)

-−1.4

No alcohol consumed

41.0
(38.5, 43.7)

24.6
(23.8, 25.5)

28.0
(25.4, 30.6)

13.0
(9.4, 16.7)

Alcohol consumed, not binge

39.0
(36.4, 41.5)

40.3
(39.5, 41.1)

37.5
(34.9, 40.0)

1.5
(-−2.1, 5.1)

Binge drinking less than once a week

15.4
(13.6, 17.4)

30.9
(30.1, 31.7)

30.6
(28.7, 32.4)

-15.2(-17.8, -−15.2
(−17.8, −12.6)

(-3.0, 0.4)

Binge drinking categoriese

Binge drinking at least once a week

4.6
(3.6, 5.9)

4.2
(3.9, 4.5)

a

Data are % (95% CI).

b

Unstandardized weighted estimates are reported and the 95% CI was constructed using bootstrap method.

c

Age- and ethno-racial-standardized expected estimates based on women od the general population from CCHS.

d

SPD: standardized prevalence difference (% (95% CI)), and the 95% CI was constructed using MOVER algorithm.

e

CHIWOS measured the last-month pattern of binge drinking, while CCHS measured the last-year pattern of binge drinking.

3.9
(3.3, 4.4)

0.7
(-−0.3, 2.1)

3.4 Drug Uuse (Table 4)
Last-month non-prescribed cannabis use in WLWH from BC was almost two times greater than the last-year use of this drug from women of the general population in BC: 14.6% vs. 6.6% reported regular use (SPD 8.0%), and
18.1% vs. 6.1% reported occasional use (SPD 12.0%). The results of last 3 months use of illicit drug use compared with last-year use of these drugs showed a higher proportion of WLWH in BC reported cocaine or crack use: 16.8% vs.
0.1% for regular use (SPD 16.7%), and 8.2% vs. 1.5% for occasional use (SPD 6.7%), regular/occasional speed use (2.5% vs. 0.1%; SPD 2.4%), and regular/occasional heroin use (11.3% vs. 0.1%; SPD 11.2%).

Table 4 Comparing illicit drug use between women living with HIV and assumed HIV-negative women of the general populationa.
alt-text: Table 4
CHIWOS

Drug useg

CCHS estimates
CCHSc

SPDe
AER Std.d

Non-prescribed cannabis useh
Regular usei

14.6
(11.3, 18.7)b

4.5
(3.4, 5.2)

6.6
(4.7, 8.6)

8.0
(4.1, 8.6)

Occasional usej

18.1
(14.4, 22.4)

7.1
(6.1, 8.1)

6.1
(4.9, 7.2)

12.0
(8.1, 16.5)

Nonek

67.3
(62.2, 72.1)

88.4
(87.2, 89.6)

87.3
(83.5, 91.1)

-20.0(-26.3, -−20.0
(−26.3, −13.9)

Regular usel

16.8
(13.2, 21.0)

0.1
(0.01, 0.2)

0.1
(0.00, 0.2)

16.7
(13.1, 20.9)

Occasional usem

8.2
(5.78, 11.61)

0.7
(0.4, 1.0)

1.5
(0.2, 2.9)

6.7
(3.9, 10.3)

None (never or former)

75.0
(70.2, 79.2)

99.2
(98.8, 99.5)

98.4
(95.0, 101.7)

-23.4(-29.2, -−23.4
(−29.2, −17.9)

Regular/occasional usel,m,n

2.5
(1.3, 4.8)

0.1
(0.01, 0.2)

0.1
(0.00, 0.2)

2.4
(1.2, 4.7)

None (never or former)

97.5
(95.2, 98.68)

99.9
(99.8, 100.0)

99.9

−2.4
(−6.2, 0.9)

Cocaine or crack use

Speed (amphetamine) use

Heroin use

(96.8, 100.0) ††-2.4(-f

Regular/occasional usel,m,n

11.3
(8.4, 15.1)

0.1
(0.02, 0.2)

0.1
(0.01, 0.2)

11.2
(8.3, 15.0)

None (never or former)

88.7
(84.9, 91.6)

99.9
(99.7, 100.0)

99.9
(96.8, 100.0)f

-11.2(-16.1, -−11.2
(−16.1, −7.0)

a

CHIWOS-BC (N = 356) and CCHS-BC (N = 7698).

b

Data are % (95% CI).

c

Unstandardized weighted estimates are reported and the 95% CI was constructed using bootstrap method.

d

Age- and ethno-racial-standardized expected estimates based on women of the general population from CCHS.

e

SPD: standardized prevalence difference (% (95% CI)), and the 95% CI was constructed using MOVER algorithm.

f

The upper limit was 102.96% but we made is to the maximum proportion 100.0%.

g

CCHS collected data for the period of last 12 months for all drugs, while CHIWOS collected data on cannabis use for last month and other drugs in last three months.

h

Any non-prescribed use of cannabis (i.e., non-medicinal, non-prescribed, self-medicating, or both medicinal and non-medicinal use simultaneously).

i

CCHS: every day or at least once a week, while it was measured as using regularly in CHIWOS.

j

CCHS: Occasional use (1-–3 times a month or less than once a month), CHIWOS: occasional use (occasionally or used but not in the past 30 days).

k
l

No non-prescribed or medicinal cannabis use.
Regular use: at least once a week.

m
n

Occasional/episodic: less than once a week.
Regular and occasional use were merged in Amphetamine and Heroin use as the absolute “n” did not meet the minimum vetting guideline.

4 Discussion
We found that a considerable proportion of WLWH reported current cigarette smoking, were intensive cigarette smokers (i.e., ≥20 cigarettes/day), reported binge drinking, and reported regular/occasional use of nonprescribed cannabis, and other illicit drugs including crack or cocaine, speed, and heroin. We also provided evidence for an excess prevalence of cigarette smoking and the use of non-prescribed cannabis, and other illicit drugs, but a
lower to similar frequency of alcohol consumption, in WLWH compared to their age- and ethnoracial group-similar general population counterparts.
While a considerable difference was found between WLWH and their general population counterparts with regard to drug use and cigarette smoking, but not hazardous alcohol drinking, we acknowledge that these differences
could in part be because of other uncontrolled population background characteristics. For example, prior studies have highlighted the contribution of socioeconomic factors (e.g., low income, unemployment) and mental health
conditions to substance among WLWH (Cook et al., 2009). Moreover, HIV-specific factors such as HIV-related stigma may play a role in substance use as a maladaptive or avoidant coping strategy (Turan et al., 2017). However, control
of these in cross-sectional analysis can be problematic in ignoring potential mediation and creating artificially similar groups that obscure real differences that can result from age (or life stage) and systemic discrimination and
differential life options across ethnoracial groups.
Our findings were consistent with the findings of the few available studies comparing WLWH with HIV-negative women. A higher proportion of cigarette smoking was found among WLWH in a 2015 US study (34.6% vs. 18.0%
were current cigarette smokers; with an age-ethnoracial-education-poverty adjusted prevalence difference of 16.6%) (Mdodo et al., 2015) and a 2014 French study (32% regular tobacco smokers, with an age-education adjusted
prevalence rate ratio of 1.32) (Tron et al., 2014). Consistent with previous research (Ikeda et al., 2016), alcohol consumption was comparatively lower in WLWH than that in the general population; however, it was still one of the most
prevalent substances reported by WLWH in the current study. The reason for the observed lower frequency of alcohol consumption among WLWH of the current study is unclear. Further research is needed to explore whether such
lower frequency of alcohol use among WLWH is due to the higher use of other drugs such as recreational cannabis use. Given the negative impacts of alcohol consumption on care and treatment outcomes (Zhang et al., 2018), our
findings in line with other studies of women with HIV (Jones et al., 2010) suggest that there is a need for screening of alcohol drinking and targeted interventions within HIV care.
The comparison of our findings on illicit drug use with extant literature is difficult because there are few such comparison analyses specifically for WLWH. However, identifying a higher prevalence of drug use in individuals
with HIV than the general population is relevant to the HIV setting, and suggests the need to ensure that factors that affect substance use among WLWH are identified and addressed and that adequate resources are provided for

addressing drug use in the context of HIV care. Limited descriptive studies have also indicated high prevalence of substance use in WLWH; for example, current cigarette smoking (56%) and concomitant use of other drugs in smokers
(24% vs. 4% in nonsmokers) (Feldman et al., 2006), past-year hazardous drinking over an 11-year follow-up period (ranged from 14% to 24%) (Cook et al., 2009), current marijuana use (from 21% to 14% over the 16-year follow-up
period) and daily marijuana use (from 3.3% to 6.1% in all studied women) (D’Souza et al., 2012). Future research could examine which factors may contribute to WLWH using or avoiding substances, including discrimination, HIVrelated stigma, intimate partner violence, and other factors that can lead to initiation or continuation of substance use. The identified substance use disparities, particularly smoking and illicit drug use, can help researchers explore
pathways leading to greater vulnerability among WLWH.
Given the contribution of substance use to suboptimal HIV outcomes, considering the mixed evidence for the role of cannabis (Bonn-Miller et al., 2014; Okafor et al., 2017), the high substance use prevalence identified in the
current research has important implications for the clinical management of HIV (Cook et al., 2008; Feldman et al., 2006). This is particularly important as substance use frequently co-presents with other health-related problems such
as psychiatric comorbidities and socio-structural barriers, that interactively impact HIV outcomes in individuals with HIV including WLWH (Cook et al., 2007; Krusi et al., 2010; Nahvi and Cooperman, 2009). These findings highlight
the need to make interventions available to women who use both drugs and antiretroviral therapy, particularly in cases where the substance use interferes with maintenance of effective HIV treatment (Sharpe et al., 2004; Zhang et al.,
2018). Integration of substance use treatment services into HIV primary care settings may contribute to enhancing the quality of HIV care and care delivery (Altice et al., 2011; Cook et al., 2008; Malta et al., 2008). Our findings also
advocate for tailored, women-centered harm reduction strategies in which women’s unique needs are effectively recognized (O’Brien et al., 2017), and peer-driven interventions through which peers can also contribute to the care and
treatment programs delivery (Simoni et al., 2011). Having access to pharmacologic and psychotropic substance use and harm reduction services through this model of care is essential to reduce use and harms of substance use
(Durvasula and Miller, 2014; Gonzalez et al., 2011; Malta et al., 2008). To improve greater involvement and adherence to treatment, one recommendation is that such a model of care delivery also provides sustained follow-up with
regular evaluations of HIV therapies to substance-using WLWH (Cohen et al., 2004; Cook et al., 2008; Sharpe et al., 2004).
This study had some limitations. CHIWOS recruited WLWH through Peer Research Associates (PRAs) – a non-random sampling design. Additionally, self-report data on substance use, a potentially stigmatizing behavior, is
subject to social desirability bias; however, this concern might have been mitigated in CHIWOS by using the PRAs, who also shared the experience of living with HIV. This was an attempt to build trust with WLWH, to allow for them to
better contribute to the research in sharing their sensitive information (Webster et al., 2018). Moreover, we compared the measure of substance use in WLWH with the assumed HIV-negative women of the general population. Because
of small population estimates of WLWH in Canada – 97 per 100,000 females (Public Health Agency of Canada, 2015), the inclusion of WLWH in the assumed HIV-negative group would not substantially change our estimates.
Furthermore, while CHIWOS collected data on cisgender (non-trans) women and trans women with HIV, CCHS does not contain data identifying trans women; therefore, it is both likely that there are also trans women in CCHS and it
is impossible to adjust for gender identity.
In conclusion, substance use was prevalent among women living with HIV, with prevalence of cigarette smoking and illicit drug use in excess of what would be expected, but not of alcohol consumption and binge drinking. Due
to their negative impacts on HIV outcomes, morbidity, and mortality, these results highlight the need for future research and programming to better understand factors that may contribute to substance use within the group of WLWH,
and to intervene on these factors, or on health risk factors within HIV care settings. Future research may also be useful in identifying substance users through screening methods, in educating HIV care providers concerning screening
for substance use problems, and in addressing specific causal pathways for the use of substances and their impacts on HIV outcomes.
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Highlights
• Women with HIV (WLWH) were 26.8% excess daily smokers vs. general population women.
• WLWH were 8.0% excess regular cannabis users vs. general population women.
• WLWH were 16.7% excess regular crack/cocaine users vs. general population women.

• WLWH were 11.2% excess regular heroin users vs. general population women.
• Alcohol use was either similar or lower in WLWH vs. general population women.
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